Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,294 papers from all fields of science
Search
Sign In
Create Free Account
Anti-EGFR Monoclonal Antibody Mixture Sym004
Known as:
Futuximab/Zatuximab
, Sym004
A mixture of two recombinant IgG1 antibodies directed against different epitopes in the epidermal growth factor receptor (EGFR) extracellular domain…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
antigen binding
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
123PGenotyping circulating tumor DNA identifies metastatic colorectal cancer (mCRC) patients highly sensitive to Sym004
C. M. Viladot
,
A. Bardelli
,
+16 authors
J. Tabernero
2017
Corpus ID: 79777581
2016
2016
Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines
S. Fukuoka
,
T. Kojima
,
+8 authors
A. Ohtsu
OncoTarget
2016
Corpus ID: 1756501
Epidermal growth factor receptor (EGFR) is a well-validated oncological target molecule for monoclonal antibody therapies and…
Expand
2016
2016
Abstract 2149: The anti-EGFR antibody mixture Sym004 overcomes acquired resistance to cetuximab in colorectal cancer
F. J. Sánchez-Martín
,
A. Dalmases
,
+18 authors
C. Montagut
2016
Corpus ID: 59080752
The anti-EGFR monoclonal antibodies (MoAbs) cetuximab and panitumumab are used to treat ‘RAS’ wild type metastatic colorectal…
Expand
Review
2015
Review
2015
Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer
K. Rihawi
,
R. Giampieri
,
+5 authors
G. Aprile
Expert Opinion on Investigational Drugs
2015
Corpus ID: 25879556
Introduction: Although epidermal growth factor receptor (EGFR) inhibitors have progressively become a relevant therapeutic arm in…
Expand
2015
2015
Abstract 1669: Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines
S. Fukuoka
,
T. Kojima
,
+9 authors
A. Ohtsu
2015
Corpus ID: 79283465
2015
2015
Sym004: Truly a New Level of Anti-EGFR Treatment?
S. Stintzing
,
V. Heinemann
Cancer Discovery
2015
Corpus ID: 31059553
Sym004 is a new antibody mixture to target EGFR in metastatic colorectal cancer. Preclinical data suggest efficacy in anti-EGFR…
Expand
2014
2014
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
G. Argilés
,
R. Dienstmann
,
+7 authors
R. Carbonero
2014
Corpus ID: 59550514
3551 Background: Preclinical models suggest that WT KRAS mCRC may retain EGFR dependency despite resistance developed to anti…
Expand
2013
2013
Proof-of-concept study of Sym004, an anti-EGFR monoclonal antibody (mAb) mixture, in patients (pts) with anti-EGFR mab-refractory KRAS wild-type (wt) metastatic colorectal cancer (mCRC).
R. Dienstmann
,
J. Tabernero
,
+9 authors
R. García-Carbonero
2013
Corpus ID: 78569491
3551 Background: KRAS wt mCRC pts progressing on chemotherapy and anti-EGFR mAbs have limited treatment options. Sym004 is a…
Expand
2012
2012
Abstract 2720: Sym004, a novel anti-EGFR antibody mixture augments radiation response in human lung and head and neck cancer models
Shyhmin Huang
,
E. Armstrong
,
M. Kragh
,
M. W. Pedersen
,
P. Harari
2012
Corpus ID: 75963400
Sym004* is a newly developed EGFR targeting agent that is a mixture of two anti-EGFR antibodies directed against distinct…
Expand
2011
2011
Phase I trial of the first-in-class EGFR antibody mixture, Sym004, in patients with advanced solid tumors.
R. Dienstmann
,
A. Tolcher
,
+8 authors
A. Patnaik
Journal of Clinical Oncology
2011
Corpus ID: 27204493
3089 Background: Sym004 is a recombinant antibody 1:1 mixture of two chimeric anti-EGFR mAbs, which elicits superior cancer cell…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE